Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients

Multiple Sclerosis Clinical Trial

— CAMA-2  

Official title:

Phase III A Prospective, Longitudinal, Rater-blinded Single-arm Study to Evaluate Alemtuzumab as an Effective Treatment in Stabilizing Overall Neurocognitive Function in RRMS Subjects at Specified Timepoints

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01333358
• Other study ID #: IND 111746
• Status: Not yet recruiting
• Phase: Phase 3
• First received: April 8, 2011
• Last updated: April 22, 2011
• Start date: May 2011
• Est. completion date: March 2014

Study information

• Verified date: April 2011
• Source: Central Texas Neurology Consultants
• Contact: Lori Mayer, RN, MSCN, CCRP
• Phone: 512-218-1222
• Email: lorimayer[@]sbcglobal.net
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The main purpose of this research study is to investigate how well a medicine (alemtuzumab) works in treating MS-related cognitive problems (e.g., attention, memory, speed of thinking). This study will include 30 subjects from six research sites.

Alemtuzumab is approved and sold under the brand names Campath and MabCampath to treat some types of leukemia. As a leukemia treatment, it is given more often and at much higher doses than in this study.

Description:

The current proposal is to conduct a study using a battery of neuropsychological tests capable of detecting the broad range of cognitive difficulties associated with relapsing remitting multiple sclerosis. This study will compare cognitive functioning over time of patients receiving alemtuzumab. The study will also compare the change in cognitive functioning over time to that of relapsing remitting multiple sclerosis patients receiving interferon beta-1a and normal controls enrolled in a parallel study conducted by Wilken et al.To evaluate cognitive effects of alemtuzumab, the investigators will perform neurological exams and brain scans and will administer questionnaires to measure the severity of multiple sclerosis, how well subjects are functioning, how they are feeling, and to find out about what other medical visits subjects may have had during the study. Neurological testing in this study will require the subject to perform relatively simple tasks to evaluate their multiple sclerosis. These tasks include a five hundred meter walk, a timed twenty five foot walk, a nine hole peg test, an eye exam, and a test requiring you to add small numbers in your head quickly. The brain scans will involve Magnetic Resonance Imaging and are painless, except for injection of a contrast agent called gadolinium, which is necessary to detect areas in the brain where their MS may be currently active. Magnetic Resonance Imaging is widely used to diagnose and assess patients with multiple sclerosis. All patients will be required to return to their study site every 3 months for assessments and testing. In addition, safety-related blood tests will be performed at least monthly. If their blood test results become abnormal, they may have to have blood tests taken more frequently, in some cases weekly, until test results improve. Monthly blood tests should be performed at your study site, but if subjects are unable to return to the study site for the blood testing, they may be able to use a local laboratory.

Participation in this study should last at least 4 years and possibly longer.

Subjects receiving alemtuzumab, will need to have blood tests every month for at least 3 years after your last dose of alemtuzumab. Therefore, you will need to undergo monthly blood tests for a total of about 4 years. If your test results become abnormal, you may have to have blood tests more frequently, in some cases weekly, until your test results improve.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: March 2014
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Signed informed consent form (ICF)

2. Age 18 to 55 years old (inclusive) as of the date the ICF is signed

3. Diagnosis of MS per McDonald criteria (2005 update).

4. Onset of MS symptoms (as determined by a neurologist, at present or retrospectively) within 10 years of the date the ICF is signed

5. EDSS score 0.0 to 5.0 (inclusive) at Screening

6. = 2 MS attacks (first episode or relapse) occurring in the 24 months prior to the date the ICF is signed, with = 1 attack in the 12 months prior to the date the ICF is signed, with objective neurological signs confirmed by a physician, nurse practitioner, or other sponsor-approved health-care provider. The objective signs may be identified retrospectively.

7. = 1 MS attack (relapse) during treatment with a beta interferon therapy or glatiramer acetate after having been on that therapy for = 6 months within 10 years of the date the ICF is signed

8. MRI scan demonstrating white matter lesions attributable to MS and meeting at least 1 of the following criteria, as determined by the neurologist or a radiologist

• = 9 T2 lesions at least 3 mm in any axis

• a gadolinium-enhancing lesion at least 3 mm in any axis plus > 1 brain T2 lesions

• a spinal cord lesion consistent with MS plus > 1 brain T2 lesions

9. Corrected vision of subjects must be no worse than 20/50.

10. Participants must have at least 10 years of education.

11. Participants must be capable of writing and pressing the buttons on a computer mouse.

12. Participants must be capable of understanding and following all test instructions.

Exclusion Criteria:

Patients will be excluded from enrollment in this study if they meet any of the following criteria:

1. Previous treatment with alemtuzumab

2. Current participation in another clinical study or previous participation in CAMMS323

3. Treatment with natalizumab, methotrexate, azathioprine, or cyclosporine in the past 6 months. Patients who received one of these medications more than 6 months before the date the ICF is signed may be eligible for study entry if approval is granted by the sponsor

4. Previous treatment with mitoxantrone, cyclophosphamide, cladribine, rituximab or any other immunosuppressant or cytotoxic therapy (other than steroids)

5. Previous treatment with any investigational medication (drug has not been approved at any dose or for any indication) unless prior approval is granted by the sponsor and the patient completes any required washout. Use of an investigational medication that was subsequently licensed and nonstandard use of a licensed medication (eg, using a dose other than the dose that is stated in the licensed product labeling or using a licensed therapy for an alternative indication) is not exclusionary. Prior treatment with herbal medications or nutritional supplements is also permitted.

6. Any progressive form of MS

7. History of malignancy, except basal skin cell carcinoma

8. Any disability acquired from trauma or another illness that, in the opinion of the Investigator, could interfere with evaluation of disability due to MS

9. Previous hypersensitivity reaction to any immunoglobulin product

10. Known allergy or intolerance to interferon beta, human albumin, or mannitol

11. Intolerance of pulsed corticosteroids, especially a history of steroid psychosis

12. Inability to self-administer SC injections or receive SC injections from caregiver

13. Inability to undergo MRI with gadolinium administration

14. Confirmed platelet count < the lower limit of normal (LLN) of the evaluating laboratory at Screening or documented at <100,000/µL within the past year on a sample without platelet clumping

15. Absolute neutrophil count < LLN at Screening; if abnormal cell count returns to within normal limits, eligibility may be reassessed

16. Known bleeding disorder (eg, dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrand's disease, disseminated intravascular coagulation [DIC], fibrinogen deficiency, clotting factor deficiency)

17. Seropositivity for human immunodeficiency virus (HIV)

18. Significant autoimmune disease including but not limited to: immune cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders, vasculitis, inflammatory bowel disease, severe psoriasis.

19. Active infection, eg, deep-tissue infection, that the Investigator considers sufficiently serious to preclude study participation

20. In the Investigator's opinion, is at high risk for infection (eg, indwelling catheter, dysphagia with aspiration, decubitus ulcer, history of prior aspiration pneumonia or recurrent urinary tract infection)

21. Latent tuberculosis unless effective anti-tuberculosis therapy has been completed, or active tuberculosis.

22. Infection with hepatitis C virus

23. Past or present hepatitis B infection (positive hepatitis B serology)

24. Of childbearing potential with a positive serum pregnancy test, pregnant, or lactating

25. Unwilling to agree to use a reliable and acceptable contraceptive method throughout the study period (fertile patients only). Reliable and effective contraceptive method(s) include: intrauterine device (IUD), hormonal based contraception, surgical sterilization, abstinence, or double-barrier contraception (condom and occlusive cap (diaphragm or cervical cap with spermicide).

26. Major psychiatric disorder that is not adequately controlled by treatment

27. Epileptic seizures that are not adequately controlled by treatment

28. Major systemic disease or other illness that would, in the opinion of the Investigator, compromise patient safety or interfere with the interpretation of study results, e.g., current peptic ulcer disease, or other conditions that may predispose to hemorrhage

29. Medical, psychiatric, cognitive, or other conditions that, in the Investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study

30. Prior history of invasive fungal infections

31. Cervical high risk human papillomavirus (HPV) positivity or abnormal cervical cytology other than abnormal squamous cells of undetermined significance (ASCUS). The patient may be eligible after the condition has resolved (e.g., follow-up HPV test is negative or cervical abnormality has been effectively treated).

32. Any other illness or infection (latent or active) that, in the Investigator's opinion, could be exacerbated by either study medication

33. Any hepatic or renal function value grade 2 or higher at Screening, with the exception of hyperbilirubinemia due to Gilbert's syndrome, unless, in the Investigator's opinion, the abnormality is due to a condition that has resolved (eg, recent interferon treatment subsequently discontinued) and levels return to within normal limits. See Table below, drawn from the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE), published 09 August 2006.

• Hepatic

• Bilirubin > 1.5 × ULN

• SGOT/AST > 2.5 × ULN

• SGPT/ALT > 2.5 × ULN

• Alkaline phosphatase > 2.5 × ULN

• Renal

• Creatinine > 1.5 × ULN

34. Participants with upper extremity dysfunction which prohibits them from using a computer mouse.

35. Participants who are colorblind.

36. Participants with current alcohol/substance abuse.

37. Participants taking medications with notable adverse CNS effects such as excessive sedation.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Sclerosis

Intervention

Drug:
• Alemtuzumab
Alemtuzumab 12mg given intravenously each day for five days and again twelve months later for an additional three days

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Central Texas Neurology Consultants	Genzyme, a Sanofi Company

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary study objective is to demonstrate whether treatment with alemtuzumab is effective in stabilizing overall neurocognitive functioning in relapsing-remitting multiple sclerosis over time.	To determine the rate of change in cognitive scores for RRMS participants taking alemtuzumab over time. The data from participants in this trial will be compared to data from normal controls and RRMS patients receiving Rebif® in a parallel trial conducted by Wilken et al (in preparation).	Four years	No